Are you Dr. Cascone?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 24 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Tina Cascone, MD is a hematologist in Houston, Texas. She is currently licensed to practice medicine in Texas, Alabama, and Arizona. She is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2012 - 2014
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2027
GA State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 2016 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Start of enrollment: 2019 Nov 05
- Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer Start of enrollment: 2020 Aug 05
Publications & Presentations
PubMed
- Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer.Tina Cascone, William N William Jr
Nature Reviews. Clinical Oncology. 2024-12-03 - Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment.Zahraa Rahal, Yuejiang Liu, Fuduan Peng, Sujuan Yang, Mohamed A Jamal
Cancer Immunology Research. 2024-12-03 - Why and When Do We Invasively Restage After Neoadjuvant Chemoimmunotherapy?Jonathan D Spicer, Tina Cascone, Murry W Wynes, Karen L Kelly
Journal of Thoracic Oncology. 2024-12-01
Press Mentions
MD Anderson Research Highlights: SITC 2024 Special EditionNovember 9th, 2024- Year in Review: Non-Small Cell Lung CancerNovember 1st, 2024
- NeoCOAST-2 Trial: Durvalumab plus Novel Agents May Increase Pathologic Responses in Resectable NSCLCSeptember 13th, 2024
- Join now to see all
